Absci Reports Q3 2025 Results, Advances ABS-201 and ABS-101 Programs

Absci Corp

2025-Q3 EPS reported -$0.65 revenue$2,150,000

Reported interim Phase 1 data for ABS-101 (anti-TL1A) showing extended half-life with no serious adverse events.
Accelerated initiation of Phase 1/2a trial for ABS-201 in androgenetic alopecia to December 2025.
Expanding ABS-201 strategy to endometriosis, targeting Phase 2 start in Q4 2026 and proof-of-concept in H2 2027.
Cash, cash equivalents, and marketable securities totaled $152.5 million as of Sept 30, 2025, funding operations into H1 2028.
Net loss was $28.7 million for Q3 2025, compared to $27.4 million in Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.